Enhancing Therapy of Primary and Recurrent Tumors With Systemic Oncolytic Virus
用全身溶瘤病毒增强原发性和复发性肿瘤的治疗
基本信息
- 批准号:9047245
- 负责人:
- 金额:$ 26.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-05-07 至 2019-04-30
- 项目状态:已结题
- 来源:
- 关键词:AdoptedAnimal ModelBiologicalBlood VesselsCarboplatinCellsClinicalClinical DataClinical ProtocolsClinical TrialsClinical Trials DesignCytolysisDataDiseaseDisseminated Malignant NeoplasmDouble-Blind MethodEvolutionExcisionGoalsGrantGranulocyte-Macrophage Colony-Stimulating FactorHealthHistologyHumanImmuneImmune responseImmune systemInfusion proceduresInjection of therapeutic agentInterleukin-2IntravenousLaboratoriesLeadLesionMediatingMetastatic Neoplasm to the LiverMethodsModelingMolecular ChaperonesMusNeoplasm MetastasisOncolyticOncolytic virusesPaclitaxelPatientsPhasePhenotypePlacebo ControlPre-Clinical ModelPrimary NeoplasmPropertyProtocols documentationRadiation therapyRageRandomizedRecoveryRecurrenceRecurrent tumorRegimenRelapseReovirusResistanceResolutionSafetySeriesSiteSuggestionT-LymphocyteTestingTimeTreatment FailureViralVirotherapyVirusVirus Replicationbasecell killingchemoradiationchemotherapyclinical effectconditioningconventional therapycytokineexperienceimprovedin vivointravenous injectionkillingsmelanomamouse modelneoplastic cellnext generationnoveloncolysisoncolytic virotherapyphase I trialphase III trialpre-clinicalpressurepreventprogramsresearch studyresponsescreeningstandard of caretargeted treatmenttumor
项目摘要
DESCRIPTION (provided by applicant): Our overall goal is to develop protocols by which oncolytic viruses can be systemically delivered in patients leading to treatment of metastatic tumors. Based upon our pre-clinical experiments showing that intravenous (i.v.) delivery of oncolytic reovirus can have significant anti tumor activity in animal models, we have completed Phase I/II clinical trials, confirming that i.v. reovirus is safe in humans. Using data from these trials, our additional pre-clinical experiments showed that tumor vasculature can be conditioned for increased reovirus replication following i.v. delivery by carefully timed combination of paclitaxel chemotherapy and reovirus virotherapy, leading to a Phase I trial of carboplatin/paclitaxel and reovirus for relapsed/metastatic cancers. During the course of this trial, we observed very encouraging suggestions of possible clinical effects, as well as the emergence of aggressive recurrences in some patients who initially responded very well following the therapy. In the current proposal, we will build further on these pre-clinical and clinical data, which have, cumulatively, shown that PAC/Reo is a well tolerated, and potentially efficacious, method of deliverying oncolytic virotherapy to tumor bearing patients. Therefore, the overall hypothesis of the current proposal is that it will be possible to develop novel treatments which both improve initial tumor responses to i.v. reovirus and either prevent, or treat, aggressive tumor recurrences. To test this hypothesis, we will improve initial anti tumor responses following i.v. reovirus, in virus immune/ non-immune mice, by conditioning the host with cytokines, chemo- or radio-therapy (Aim 1) and/or chaperoning, and protecting, i.v. administered reovirus using immune cell carriers (Aim 2), in order to enhance levels, and immune consequences, of virus delivered to the tumor and/or its vasculature. In addition, we will treat recurrent tumors, which fail initial systemic virotherapy, with rational, mechanism-based 2nd line therapies by targeting the predictable recurrent tumor phenotype which emerges upon treatment failure with front line chemo-/virotherapy (Aim 3). Overall these experiments will lead to new clinical trials for i.v. delivery of reovirus and should also be directly applicable to a rage of both different tumor types and oncolytic viruses.
描述(由申请人提供):我们的总体目标是制定方案,通过该方案,溶瘤病毒可以系统地传递给患者,从而治疗转移性肿瘤。基于我们的临床前实验显示,在动物模型中静脉注射溶瘤呼肠孤病毒具有显著的抗肿瘤活性,我们已经完成了I/II期临床试验,确认静脉注射呼肠孤病毒在人类中是安全的。利用这些试验的数据,我们的其他临床前实验表明,通过精心定时的紫杉醇化疗和呼肠孤病毒病毒治疗联合静脉给药,肿瘤血管系统可以调节呼肠孤病毒复制的增加,从而导致卡铂/紫杉醇和呼肠孤病毒治疗复发/转移性癌症的I期试验。在这项试验的过程中,我们观察到非常令人鼓舞的可能的临床效果的建议,以及在一些患者中出现侵袭性复发,这些患者最初在治疗后反应非常好。在目前的提案中,我们将进一步建立这些临床前和临床数据,这些数据累积表明PAC/Reo是一种耐受性良好且潜在有效的向肿瘤患者提供溶瘤病毒治疗的方法。因此,当前建议的总体假设是,有可能开发出新的治疗方法,既能改善静脉呼肠孤病毒对肿瘤的初始反应,又能预防或治疗侵袭性肿瘤复发。为了验证这一假设,我们将在病毒免疫/非免疫小鼠中,通过使用细胞因子、化学或放射治疗(Aim 1)和/或陪伴和保护宿主,通过免疫细胞载体(Aim 2)来改善呼肠孤病毒静脉注射后的初始抗肿瘤反应,以提高病毒递送到肿瘤和/或其脉管系统的水平和免疫后果。此外,我们将针对一线化疗/病毒治疗失败后出现的可预测的复发肿瘤表型,采用合理的、基于机制的二线治疗来治疗初始全身病毒治疗失败的复发肿瘤(目标3)。总的来说,这些实验将导致静脉注射呼肠孤病毒的新的临床试验,也应该直接适用于不同类型的肿瘤和溶瘤病毒。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard G. Vile其他文献
Viral fusogenic membrane glycoproteins are a new class of therapeutic genes for the treatment of hepatocellular carcinoma (HCC)
- DOI:
10.1016/s0016-5085(00)85751-0 - 发表时间:
2000-04-01 - 期刊:
- 影响因子:
- 作者:
Hajime Higuchi;Steven F. Bronk;Richard G. Vile;Gregory J. Gores - 通讯作者:
Gregory J. Gores
Richard G. Vile的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard G. Vile', 18)}}的其他基金
Characterizing the role of CSDE1 as a critical co-factor for VSV replication.
描述 CSDE1 作为 VSV 复制关键辅助因子的作用。
- 批准号:
10650485 - 财政年份:2023
- 资助金额:
$ 26.39万 - 项目类别:
Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors.
重新调整溶瘤病毒疗法以重振实体瘤 CAR T 细胞疗法。
- 批准号:
10578864 - 财政年份:2022
- 资助金额:
$ 26.39万 - 项目类别:
Novel Strategies to Treat Diffuse Midline Glioma with CAR T Cell Therapy
利用 CAR T 细胞疗法治疗弥漫性中线胶质瘤的新策略
- 批准号:
10284722 - 财政年份:2021
- 资助金额:
$ 26.39万 - 项目类别:
Novel Strategies to Treat Diffuse Midline Glioma with CAR T Cell Therapy
利用 CAR T 细胞疗法治疗弥漫性中线胶质瘤的新策略
- 批准号:
10412129 - 财政年份:2021
- 资助金额:
$ 26.39万 - 项目类别:
Enhancing Therapy of Primary and Recurrent Tumors With Systemic Oncolytic Virus
用全身溶瘤病毒增强原发性和复发性肿瘤的治疗
- 批准号:
8687777 - 财政年份:2014
- 资助金额:
$ 26.39万 - 项目类别:
Enhancing Systemic Delivery of Oncolytic Viruses for Cancer Therapy
增强溶瘤病毒的全身递送用于癌症治疗
- 批准号:
8387981 - 财政年份:2009
- 资助金额:
$ 26.39万 - 项目类别:
Enhancing Systemic Delivery of Oncolytic Viruses for Cancer Therapy
增强溶瘤病毒的全身递送用于癌症治疗
- 批准号:
7993072 - 财政年份:2009
- 资助金额:
$ 26.39万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 26.39万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 26.39万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 26.39万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 26.39万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 26.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 26.39万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 26.39万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 26.39万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 26.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 26.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists